Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 830-217-3 | CAS number: 1393932-71-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- data waiving: supporting information
Reference
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From Oct 20, 1988 to Nov 30, 1988
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles river portage,Michigen, USA
- Age at study initiation: 4-6 weeks
- Weight at study initiation: 116-152 g
- Fasting period before study: Overnight
- Housing: Individually; metal cages with wire mesh floors
- Diet (e.g. ad libitum): Standard laboratory rodent diet(ad libitum)
- Water (e.g. ad libitum): Domestic quality portable water(ad libitum)
- Acclimation period: 14 d
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22⁰ C
- Humidity (%): 53%
- Air changes (per hr): Approx 15
- Photoperiod (hrs dark / hrs light): 12 h - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- VEHICLE
Test substance was administered as supplied by the sponsor
MAXIMUM DOSE VOLUME APPLIED: 4.5 mL/kg bw (specific gravity 1.1)
- Rationale for the selection of the starting dose: Preliminary study - Doses:
- 5000 mg/kg bw (4.54 mL/kg bw)
- No. of animals per sex per dose:
- 5/sex/dose
- Control animals:
- no
- Details on study design:
- Five males and five females were treated at 5000 mg/kg bw using syringe and plastic catheter (8 choke). Animals were observed after 5 h on day 1 and in subsequent days the animals were observed once in the morning and again at the end of the experiment. Observation period was 14 d.
- Frequency of observations and weighing: Clinical observations done soon after dosing and remainder of Day 1. For the subsequent days observations were done in the morning and at the end of the experimental day.
- Necropsy of survivors performed: Yes along with macroscopic examinations of thoracic, abdominal and cranial cavities. Marcoscopic appearance of abnormal organs was also recorded.
- Other examinations performed: Body weights of each rat was examined at Days 1, 8 and 15 or at death. - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality at 5000 mg/kg bw
- Clinical signs:
- other: other: Pilo-erection in all rats within 5 min after dosing which remained for 1 d followed by increased salivation during 1st 2 h after treatment. No other clinical signs were observed and recovery was complete by Day 3.
- Other findings:
- Terminal autopsy was normal.
- Interpretation of results:
- other: CLP criteria not met
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Under the test condition, the acute lethal oral dose of di-TMPTTA was > 5,000 mg/kg bw.
- Executive summary:
A study was conducted to assess the acute oral toxicity of di-TMPTTA according to OECD Guideline 401 and EU Method B.1, in compliance with GLP. Five males and five females were administered a single oral dose of 5,000 mg/kg bw by gavage. Animals were observed for 14 d. On Day 1, pilo-erection was seen within 5 min of dosing along with increased salivation during 2 h after treatment. Low body weight gain during the first week of the study was recorded but all rats achieved anticipated weight gains between Days 8 and 15. No other clinical signs were observed and recovery, judged by appearance and behaviour, was complete by Day 3. Under the test conditions, the acute lethal oral dose of the test substance was > 5,000 mg/kg bw (Liggett 1989).
- Reason / purpose for cross-reference:
- data waiving: supporting information
Reference
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 28 July, 1998 to 14 Aug, 1998
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- no
- Species:
- rat
- Strain:
- other: CD rats of Sprague-Dawley origin (Hsd:Sprague-Dawley(CD))
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Animals chosen for this study were selected from a stock supply of healthy male and female CD rat of Sprague-Dawley origin (Hsd:Sprague-Dawley(CD)) obtained from Harlan U.K. Ltd., Bicester, Oxon, England. They were in the weight range of 125 to 152 g and approx 5-7 weeks of age prior to dosing (Day 1). All the rats were acclimatised to the experimental environment for a minimum period of 15 d prior to the start of the study. Rats were allocated without conscious bias to cages within the treatment groups. They were housed in groups of 5 rats of the same sex in metal cages (RS biotech sub-dividable rodent cages polished stainless steel (20 cm high x 39 cm wide x 39 cm long). The cages were suspended in the mobile stainless steel racks in room 6 of building R14.
A standard laboratory rodent diet (Special Diet Services RM1(E) SQC expanded pellet) and drinking water were provided ad libitum. Access to food only was prevented overnight prior to and approx 4 h after dosing. Each batch of diet used for the study was analyzed for certain nutrients, possible contaminants and micro-organisms. Results of routine physical and chemical examination of drinking water, as conducted by the supplier are made available to Huntingdon Life Sciences Ltd. at regular intervals throughout the year. Animal room environmental controls were set to maintain temperature within the range 22 ± 3°C (actual 21 to 26°C) and relative humidity 30-70% (actual 39 to 58%). These environmental parameters were recorded continously using a 7 d recorder. Lighting was controlled by means of a time switch to provide 12 h of artificial light (0700 – 1900 GMT) in each 24 h period. Each animal was identified by cage number and ear punching. - Route of administration:
- oral: gavage
- Vehicle:
- not specified
- Details on oral exposure:
- The test substance was administered as supplied at a volume of 4.452 mL/kg bw. The observation and characterization of the homogeneity, stability and purity of the test substance was not undertaken as part of this study and remains the responsibility of the Sponsor.
- Doses:
- Preliminary study: 3200 mg/kg bw
Main study: 5000 mg/kg bw - No. of animals per sex per dose:
- Preliminary study: 2 rats (1 male and female)
Main study: 5/sex/dose - Control animals:
- no
- Details on study design:
- Preliminary study: 2 rats (one male and one female) received a single oral gavage dose of the test substance at a dose level of 3200 mg/kg bw using a syringe and plastic catheter or cannula. This was conducted to help define the toxic potential of the test substance and aid in selection of a suitable dosage for the main study.
Main study:
As results at this dosage indicated the acute lethal oral dose of the test substance to be greater than 3200 mg/kg bw, in compliance with the guidelines, a further group of 10 rats (five males and five females) was similarly dosed at 5000 mg/kg bw to complete the study. The day of dosing was designated Day 1. Cages of rats were checked at least twice daily for any mortalities. For clinical signs animals were observed soon after dosing and at frequent intervals for the remainder of Day 1. On subsequent days, animals were observed once in the morning and again at the end of the experimental day (with the exception of Day 15 - morning only). The nature and severity of the clinical signs and time were recorded at each observation. All animals were observed for 7 to 14 d after dosing. The bw of each rat was recorded on 1 (prior to dosing), 8 and 15 d. Individual weekly bodyweight changes and group mean bw were calculated. All animals were killed on Day 15 by carbon dioxide asphyxiation. All animals were subjected to a macroscopic examination which consisted of opening the thoracic and abdominal cavities. The macroscopic appearance of all examined organs was recorded. - Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- There were no deaths following a single oral gavage dose of the test substance in the preliminary or the main study at a dose level of either 3200 or 5000 mg/kg bw.
- Clinical signs:
- other: other: Preliminary study: Clinical signs of reaction to treatment comprised of abnormal piloerection, soft to liquid feces and increased salivation (in male rat only). Main study: Clinical signs of reaction to treatment comprised of abnormal piloerectio
- Gross pathology:
- No abnormalities were revealed at the macroscopic examination at study termination on Day 15 in the preliminary and the main studies.
- Interpretation of results:
- other: CLP criteria not met
- Conclusions:
- Under the conditions of the study, the acute oral lethal dose of the test substance to rats was found to be greater than 5,000 mg/kg bw.
- Executive summary:
A study was performed to assess the acute oral toxicity of di-TMPTTA to the rat according to OECD Guideline 401 and EU Method B.1, in compliance with GLP. In a preliminary test, 2 rats (one male and one female) received a single oral gavage dose of the test substance at a dose level of 3,200 mg/kg bw. As results at this dosage indicated the acute lethal oral dose of the test substance to be greater than 3,200 mg/kg bw, a further group of 10 fasted rats (five males and five females) was similarly dosed at 5,000 mg/kg bw in the main study. No abnormalities were revealed at macroscopic examination on Day 15. Under the conditions of the study, the acute lethal oral dose to rats was > 5,000 mg/kg bw (McRae 1998).
- Reason / purpose for cross-reference:
- data waiving: supporting information
Reference
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 04 April, 2012 to 07 May, 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.2600 (Skin Sensitisation)
- Deviations:
- no
- GLP compliance:
- yes
- Type of study:
- mouse local lymph node assay (LLNA)
- Species:
- mouse
- Strain:
- other: CBA/J
- Sex:
- female
- Details on test animals and environmental conditions:
- - Source: Janvier, Le Genest-Saint-Isle, France
- Age at study initiation: Young adult animals (approx 11 weeks old)
- Weight at study initiation: Body weight variation was within +/- 20% of the sex mean
- Housing: Animals were group housed in labeled makrolon cages.
- Diet: Free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany).
- Water: Free access to tap water.
- Acclimation period: At least 5 d
ENVIRONMENTAL CONDITIONS
Environmental controls for the animal room were set to maintain 18 to 24°C, a relative humidity of 40 to 70%, approx 15 room air changes/h, and a 12-h light/12-h dark cycle. Any variations to these conditions were maintained in the raw data and had no effect on the outcome of the study.
Deviations from the minimum level of daily mean relative humidity occurred. Laboratory historical data do not indicate an effect of the deviations.
IN-LIFE DATES: From: 04 April - 07 May 2012 - Vehicle:
- acetone/olive oil (4:1 v/v)
- Concentration:
- Main test concentrations: 0, 0.5, 1, 2.5%
Pre-screen test was done at doses of 0.5, 1, 2.5, 5, 10, 50 and 100%. Up to doses of 5%, ear swelling and signs of erythema were too pronounced. In the OECD TG 429, it is written “excessive local skin irritation is indicated by an erythema score ≥3 and/or an increase in ear thickness of ≥25% on any day of measurement. The highest dose selected for the main LLNA study will be the next lower dose in the pre-screen concentration series that does not induce systemic toxicity and/or excessive local skin irritation.“. In the case of di-TMPTTA, the threshold of 25% of ear thickness was exceeded at the doses of 5% and higher. Therefore the main study has been conducted with doses of 0.5, 1 and 2.5%. - No. of animals per dose:
- 5
- Details on study design:
- The vehicle was selected based on trial formulations performed at WIL Research Europe and on test substance data supplied by the sponsor.
RANGE FINDING TESTS:
Pre-screen test was done at doses of 0.5, 1, 2.5, 5, 10, 50 and 100%. Up to doses of 5%, ear swelling and signs of erythema were too pronounced. In the OECD TG 429, it is written “excessive local skin irritation is indicated by an erythema score ≥3 and/or an increase in ear thickness of ≥25% on any day of measurement. The highest dose selected for the main LLNA study will be the next lower dose in the pre-screen concentration series that does not induce systemic toxicity and/or excessive local skin irritation.“. In the case of di-TMPTTA, the threshold of 25% of ear thickness was exceeded at the doses of 5% and higher. Therefore the main study has been conducted with doses of 0.5, 1 and 2.5%.
MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: Local Lymph Node Assay
- Criteria used to consider a positive response: DPM values are presented for each animal and for each dose group. A Stimulation Index (SI) is calculated for each group. The SI is the ratio of the DPM/group compared to DPM/vehicle control group. If the results indicate a SI ≥ 3, the test substance may be regarded as a skin sensitizer. The results were evaluated according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (20011) and the Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on Classification, Labelling and Packaging of substances and mixtures.
ANIMAL ASSIGNMENT
Three groups of five animals were treated with one test substance concentration per group. One group of five animals was treated with vehicle.
TREATMENT PREPARATION AND ADMINISTRATION:
Test substance preparation: The test substance formulations (w/w) were prepared within 4 h prior to each treatment. Homogeneity was obtained to visually acceptable levels.
Rationale for vehicle: The vehicle was selected based on trial formulations performed at WIL Research Europe and on test substance data supplied by the sponsor.
Induction - Days 1, 2 and 3; Excision of nodes - Day 6; Tissue processing for radioacitivity - Day 6; Radioactivity measurements - Day 7; Performed according to test guidelines.
Observations:
Mortality/Viability: Twice daily.
Body weights: On Day 1 (pre-dose) and Day 6 (prior to necropsy).
Clinical signs: Once daily on Days 1-6 (on Days 1-3 between 3 and 4 h after dosing).
Irritation: Once daily on Days 1-6 (on Days 1 - 3 immediately after dosing) according to the following numerical scoring system. Furthermore, a description of all other (local) effects was recorded according to guidelines. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Positive control results:
- The six-month reliability check with alpha-hexylcinnamicaldehyde indicates that the Local Lymph Node Assay as performed at WIL Research Europe is an appropriate model for testing for contact hypersensitivity. See attached document 'Reliability check'.
- Key result
- Parameter:
- SI
- Value:
- ca. 0.9
- Variability:
- five animals
- Test group / Remarks:
- 0.5% test substance
- Parameter:
- other: disintegrations per minute (DPM)
- Value:
- ca. 448 - ca. 1 174
- Variability:
- Mean DPM/animal values
- Test group / Remarks:
- 0.5, 1 and 2.5% test substance
- Remarks on result:
- other: Mean DPM/animal values for the experimental groups treated with test substance concentrations 0.5, 1 and 2.5% were 448, 613 and 1174 DPM respectively. The mean DPM/animal value for the vehicle control group was 524 DPM.
- Key result
- Parameter:
- SI
- Value:
- ca. 1.2
- Variability:
- five animals
- Test group / Remarks:
- 1% test substance
- Key result
- Parameter:
- SI
- Value:
- ca. 2.2
- Variability:
- five animals
- Test group / Remarks:
- 2.5% test substance
- Interpretation of results:
- other: CLP criteria not met
- Conclusions:
- In a mouse LLNA study, SI values calculated for the concentrations of 0.5, 1 and 2.5% di-TMPTTA were 0.9, 1.2 and 2.2, respectively. These results indicate that the test substance did not elicit an SI ≥ 3. The substance is therefore not considered to be sensitizing.
- Executive summary:
A study was conducted to assess the skin sensitizing potential of di-TMPTTA in a mouse local lymph node assay conducted according to OECD Guideline 429, EU Method B.42 and EPA OPPTS 870.2600, in compliance with GLP. Five animals per dose were exposed to the test substance at 0.5, 1.0 or 2.5%. The slight irritation of the ears observed on Days 2 and 3 in all animals treated at 2.5% was not considered to have a toxicologically significant effect on the activity of the nodes. No irritation was shown by the other animals. All auricular lymph nodes of the animals of the experimental and control groups were considered normal in size. No macroscopic abnormalities of the surrounding area were noted. Mean degradations per minute (dpm)/animal at 0.5, 1 and 2.5% were 448, 613 and 1,174, respectively. The mean dpm/animal for the vehicle control group was 524. The SI values calculated for the substance concentrations of 0.5, 1.0 and 2.5% were 0.9, 1.2 and 2.2, respectively. Since there was no indication that the test substance could elicit an SI ≥ 3 when tested up to 2.5%, it was established that the EC3 value (the estimated test substance concentration that will give a SI =3) exceeds 2.5%. The substance was therefore not considered to be sensitizing (Beerens 2013).
Results pre-screen test:
Based on the results obtained in this test, the highest test substance concentration selected for the main study was a 2.5% concentration
Other results - main study:
Skin reactions / Irritation:
The slight irritation of the ears as shown by all animals treated at 2.5% (on Days 2 and 3) was considered not to have a toxicologically significant effect on the activity of the nodes. No irritation was shown by the other animals.
Systemic toxicity/Body weights:
No mortality occurred and no clinical signs of systemic toxicity were observed in the animals of the main study. Body weights and body weight gain of experimental animals remained in the same range as controls over the study period. The body weight loss noted across the dose groups was considered not toxicologically significant since the changes were slight in nature and no concentration-related incidence was apparent.
Macroscopy of the auricular lymph nodes and surrounding area:
All auricular lymph nodes of the animals of the experimental and control groups were considered normal in size. No macroscopic abnormalities of the surrounding area were noted in any of the animals.
Data source
Materials and methods
Results and discussion
- Clinical signs:
- other: other:
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.